UNAM Researchers Unveil Novel Antibiotics Derived from Scorpion Venom and Habanero Peppers

Researchers at the National Autonomous University of Mexico (UNAM) have identified three new antibiotic compounds derived from natural sources to combat drug-resistant bacteria. The breakthrough involves two benzoquinone molecules isolated from the venom of the Diplocentrus melici scorpion, which demonstrated efficacy against Mycobacterium tuberculosis and Staphylococcus aureus. Concurrently, a separate team identified a peptide named defensin J1-1 within habanero peppers (Capsicum chinense), which proved effective against Pseudomonas aeruginosa.

The scorpion-derived molecules present a unique chemical property where they oxidise and change colour upon exposure to air, allowing scientists to confirm their structure. The blue variant targets tuberculosis bacteria, while the red variant targets Staphylococcus aureus. Further testing revealed that the blue benzoquinone is also capable of eliminating Acinetobacter baumannii, a highly resistant opportunistic pathogen often associated with hospital-acquired infections.

Patents have been secured in Mexico and South Africa for the scorpion-derived compounds, while the pepper-derived peptide holds a patent in Mexico. These intellectual property protections mark a significant step in addressing antimicrobial resistance, with the research team now focusing on developing stabilising nanoparticles to ensure safe administration of the treatments.

The development of the pepper-based antibiotic followed a distinct biotechnological approach. Scientists led by Gerardo Corzo Burguete and Georgina Estrada Tapia utilised a process involving genetically modified bacteria cultured via submerged fermentation to mass-produce defensin J1-1. This method allowed for the extraction and purification of the peptide, which showed potential to treat infections caused by fungi as well as the targeted bacterium.

Despite positive experimental results, the researchers acknowledged specific limitations that must be addressed before human application. The study on the pepper peptide utilised a laboratory strain of Pseudomonas aeruginosa rather than a resistant strain isolated directly from patients. Additionally, the molecules may be degraded in different organisms, necessitating further research to validate their therapeutic potential against clinical isolates.

The next critical phase involves conducting clinical trials, which require significant investment and potential collaboration with national pharmaceutical companies for large-scale production. Researchers are currently working on stabilising nanoparticles to protect the compounds within the body, aiming to bring these innovative treatments from the laboratory to patients who require them most.